Growth-Hormone Signaling
Growth-hormone pathways, made understandable.
These compounds affect GHRH, ghrelin-receptor, or IGF signaling. Their evidence, approved uses, and safety profiles differ substantially.
CJC-1295 (no DAC)
A short-acting GHRH analogue studied for effects on pulsatile growth-hormone signaling. It is not FDA-approved.
Ipamorelin
A growth-hormone secretagogue studied for selective ghrelin-receptor activity. It is not FDA-approved.
CJC-1295 + Ipamorelin
A blend combining GHRH and ghrelin-receptor signaling. The combination is not FDA-approved.
Sermorelin
A GHRH analogue used to stimulate the body’s own growth-hormone release. Current compounded preparations are not FDA-approved.
Tesamorelin
An FDA-approved medicine exists for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Other uses and custom preparations are not FDA-approved.
Tesamorelin + Ipamorelin
A custom blend studied for combined GHRH and ghrelin-receptor signaling. The combination is not FDA-approved.
IGF-1 LR3
A long-acting IGF-1 analogue used in laboratory research. It is not FDA-approved for human use.
Educational information only. Hormone-signaling therapies can carry meaningful risks and require careful clinician assessment, monitoring, and lawful sourcing.